Curis to Present at Upcoming Healthcare Conferences in September
- None.
- None.
The H.C. Wainwright 25th Annual Global Investment Conference being held September 11 – 13, 2023. Presentation details are as follows:
- Format: Company Presentation
- Date: Tuesday, September 12, 2023
- Time: 8:30am ET
The 2023 Cantor Global Healthcare Conference being held September 26 – 28, 2023. Presentation details are as follows:
- Format: Panel Presentation
- Date: Wednesday, September 27, 2023
- Time: 9:10am ET
Webcasts will be available on the Curis website at www.curis.com in the 'Investors' section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-301919160.html
SOURCE Curis, Inc.